Logo image of MDLA

Medallia Inc (MDLA) Stock Fundamental Analysis

NYSE:MDLA -

33.99
+0.02 (+0.06%)
Last: 10/28/2021, 8:53:36 PM
33.9999
+0.01 (+0.03%)
After Hours: 10/28/2021, 8:53:36 PM
Fundamental Rating

3

Taking everything into account, MDLA scores 3 out of 10 in our fundamental rating. MDLA was compared to 283 industry peers in the Software industry. While MDLA seems to be doing ok healthwise, there are quite some concerns on its profitability. MDLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MDLA has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -14.41%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -34.44%
PM (TTM) -37.34%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for MDLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.71 indicates that MDLA is not a great score, but indicates only limited risk for bankruptcy at the moment.
There is no outstanding debt for MDLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

MDLA has a Current Ratio of 1.84. This is a normal value and indicates that MDLA is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio N/A

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MDLA have decreased strongly by -950.00% in the last year.
The Revenue has grown by 18.83% in the past year. This is quite good.
MDLA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.25% yearly.
EPS 1Y (TTM)-950%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
Revenue 1Y (TTM)18.83%
Revenue growth 3Y22.25%
Revenue growth 5YN/A
Sales Q2Q%24.74%

3.2 Future

MDLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 91.00% yearly.
Based on estimates for the next years, MDLA will show a very strong growth in Revenue. The Revenue will grow by 20.67% on average per year.
EPS Next Y-682.76%
EPS Next 2Y-20.69%
EPS Next 3Y60.67%
EPS Next 5Y91%
Revenue Next Year20.49%
Revenue Next 2Y19.81%
Revenue Next 3Y21.03%
Revenue Next 5Y20.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MDLA Yearly Revenue VS EstimatesMDLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
MDLA Yearly EPS VS EstimatesMDLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0 0.2 0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDLA. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 1801.27, MDLA can be considered very expensive at the moment.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.82, MDLA is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 1801.27
MDLA Price Earnings VS Forward Price EarningsMDLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 500 1K 1.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -49.39
MDLA Per share dataMDLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

MDLA's earnings are expected to grow with 60.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.69%
EPS Next 3Y60.67%

More info and screens

0

5. Dividend

5.1 Amount

MDLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Medallia Inc

NYSE:MDLA (10/28/2021, 8:53:36 PM)

After market: 33.9999 +0.01 (+0.03%)

33.99

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.34%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.47B
Analysts60
Price Target34.68 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1801.27
P/S 10.43
P/FCF N/A
P/OCF N/A
P/B 15.34
P/tB N/A
EV/EBITDA -49.39
EPS(TTM)-0.17
EYN/A
EPS(NY)0.02
Fwd EY0.06%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.26
BVpS2.22
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -34.44%
PM (TTM) -37.34%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio N/A
Altman-Z 2.71
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-950%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1000%
EPS Next Y-682.76%
EPS Next 2Y-20.69%
EPS Next 3Y60.67%
EPS Next 5Y91%
Revenue 1Y (TTM)18.83%
Revenue growth 3Y22.25%
Revenue growth 5YN/A
Sales Q2Q%24.74%
Revenue Next Year20.49%
Revenue Next 2Y19.81%
Revenue Next 3Y21.03%
Revenue Next 5Y20.67%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A